SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced a strategic transaction to exclusively ...

Expanded Functionality to Support COVID-19 Research Immediately Available Through Early Access “ROSALIND offers powerful data analysis capabilities and a unique ability to facilitate collaboration ...

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of its second generation ...

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products ...

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of a Single Cell Gene ...

More than 35 Abstracts Demonstrate the Value of the nCounter Platform for Targeted Discovery, Biomarker Development and Diagnostic Applications in Cancer Research and Immuno-Oncology NanoString’s New ...

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ...

45 Abstracts Demonstrate the Value of the nCounter Platform for Immuno-Oncology Research Studies Indicate the Clinical Relevance of the Tumor Inflammation Signature for Multiple Immunotherapies ...

Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently endorse routine ...